Evicenter
MarkdownMedical informationP&T meetings
Rinzimetostat (ORIC-944)

Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide

Regulatory status
Not announced
Launch
Not announced
Last updated
165 sources

Product information and disease descriptionProduct description

Product information

85 evidence topics · 40 sources

Average sales price and wholesale acquisition cost

Not applicable.

Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions

Not applicable.